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ABSTRACT
Motor neuron disease (MND) is a progressive degenerative disorder of the motor neurons, resulting in progressive limb,
bulbar and respiratory muscle weakness. No definitive disease modifying treatment is available at this time. The
mainstay of management remains multidisciplinary care, which has shown to improve quality of life, prevents
complications and may also increase life span.
In this review, different medical specialties necessary to offer complete multidisciplinary care are discussed.
Symptomatic management of individual symptoms commonly experienced by patients with MND is elaborated on.
KEYWORDS: Motor neuron disease, multidisciplinary clinic, nutrition, respiratory support, speech
INTRODUCTION: Despite recent advances in the
availability of approved drugs for the treatment of motor
neuron disease (MND)/Amyotrophic lateral sclerosis
(ALS), symptomatic treatment remains the main stay
for the management of these patients.(1) MND can
present with asymmetric or symmetric limb weakness
or can have its onset in the bulbar muscles with speech
and swallowing difficulties. This is a progressive
degenerative disorder of motor neurons residing in the
motor cortex, brain stem and anterior horns. Presenting
symptoms and progression of the disease varies
amongst individuals, possibly influenced by genetic and
environmental factors. The median survival, from
symptom onset to death, ranges from 20 to 48
months. (2) Only 10% patients with ALS live over 10
years of disease duration. (2) Older age and bulbar
symptoms at onset are poor prognostic factors. (2)
Overtime it has become clear that MND is not just a
disorder of motor neuron degeneration but involves
other brain regions too. For example, patients suffer
from behavioral and cognitive issues at some point
during their illness as a result of degeneration of the
frontal lobes.(3) Therefore management of MND needs
a holistic multi-disciplinary approach.
Multidisciplinary care of patients with MND has shown
to improve quality of life, decrease complications and

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

hospitalizations, prolong survival and decrease
mortality.(1, 4-6) This review aims to describe the
components necessary for successful multidisciplinary
management of patients with MND and the evidence
behind timely supportive interventions.
MULTIDISCIPLINARY CLINICS
Successful multidisciplinary care of MND/ALS requires
specialized clinics where a patient is systematically
evaluated by multiple specialists on the same day. A
multidisciplinary clinic (MDC) decreases the burden on
patients and care givers who would otherwise be
compelled to go to different specialists, at different
locations and times. A MDC provides co-ordinated care
and typically includes assessment and management by
multiple team members. (7, 8) At the end of the clinic,
ideally, the team discusses individual specialty
recommendations and comes up with a health care
plan for the patient. Each team member has defined
goals: (7, 8)
1. Neurologist: responsible for diagnosis, breaking the
news, clinical monitoring, prescribing medications,
co-ordination with other health care personnel,
discussing scientific evidence, answering questions and
provide information about enrollment in clinical trials. It
is useful to assess the patient based on a scale such as
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the ALS functional rating scale- revised (ALSFRS-R) to
document the disease course.
2. Speech and language therapist: evaluates oral
motor and swallowing function, gives advice for
oropharyngeal exercises, is responsible for early
detection of dysphagia and works with the patients on
developing long term strategies for communication.
3. Nutritionist: monitors body mass index (BMI), caloric
intake and provides the patient and family with a dietary
plan to follow. They work in close association with the
speech therapist for appropriate dietary advice
according to the swallowing status. Maintaining BMI is
important as rapid weight loss is considered a poor
prognostic factor.
4. Physiotherapist (PT): assess mobility, physical
strength and devise a home care exercise plan.
5. Occupational therapist (OT): works in association
with the PT and assess home safety and performance
of activities of daily living. PT and OT together assess
and advice for the need of assistive devices to help with
daily activities.
6. Neuropsychologist/psychiatrist: responsible for early
detection of mood, behavioral and cognitive changes,
helps with end of life decisions and provides emotional
support for the patient and family.
7. The nurse manager and social worker works as a
liaison between the patient and health care team.
The team works in close contact with a palliative care
specialist, gastroenterologist and pulmonologist for
timely intervention with percutaneous gastrostomy
(PEG) and/or non-invasive ventilation (NIV) respectively.

Besides disease modifying agents, specifically Riluzole
(9)and possibly Edaravone(10), the mainstay of
management for all MND patients remains optimal care
for evolving symptoms. The aim is to improve quality of
life of the patient and family, prevent complications and
decrease hospitalizations.
RESPIRATORY SUPPORT
Just like other skeletal muscles, respiratory muscles
also become progressively weak in MND. Inspiration is
an active process, requiring contraction of intercostal,
diaphragmatic and accessory muscles to generate a
negative intrathoracic pressure and allow air inflow.
(11) Upper motor neurons further control and modify
the pattern of breathing. As a result of progressive
weakness of respiratory muscles and loss of upper
motor neurons, patients experience symptoms such as
shortness of breath on exertion, orthopnoea,
non-refreshing sleep, morning headaches and loss of
appetite. Even asymptomatic patients can have
respiratory muscle weakness (12), making regular
screening of these patients all the more important,
even in early stages of the disease. Neuromuscular
respiratory failure is the most common cause of death
in patients with MND/ALS. (11, 18)
In a landmark randomized control trial conducted by
Bourke et al (13), non-invasive ventilations ( NIV)
significantly improved quality of life and survival in
patients with non-bulbar ALS. Similar survival benefits
were not seen in patients with bulbar symptoms;
however there was improvement in sleep related
symptoms in this group. (13) A recent Cochrane review
(14) corroborated these findings with some suggestion
that patients who have not yet developed respiratory
symptoms or have mild respiratory muscle involvement
may have a higher survival benefit and improvement in
quality of life, however this is still under
investigation.(14) NIV works by improving oxygenation,
decreasing work of breathing and fatigue, improving
lung compliance and reversing hypercapnia thereby
improving central respiratory drive. (11) NIV should be
offered to patients in a timely manner, before they
develop frank respiratory failure in order to obtain the
maximum quality of life and prolong survival.
Assessment of respiratory function through symptoms,
oxygen saturation, forced vital capacity (FVC) and
maximal inspiratory pressure (MIP) is recommended at
the time of diagnosis and at every 3 months follow up.
Nocturnal oximetry should be considered in doubtful
cases. The predicted FVC and a decline in FVC is the
most important predictor of survival. (19) Ideally FVC
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should be recorded both sitting and supine and a 25%
drop in FVC in the supine position strongly suggests
diaphragmatic weakness.(1) Patients who full fill the
criteria of neuromuscular respiratory failure i.e., those
with orthopnea, MIP < -60cm, FVC <50% predicted or
abnormal nocturnal oximetry require NIV. (1)
The most common setting of NIV used is bi-level
positive airway pressure (BIPAP). Compliance and
tolerance to NIV can be an issue. Individuals with
bulbar onset MND may experience difficulty in
tolerating BIPAP due to pooling of secretions and weak
cough, which in turn can result in a lot of anxiety.(15)
Those with cognitive decline or frontotemporal
dementia may show low adherence to the use of
NIV.(15) Therefore a mutual decision needs to be made
after extensive counseling of the patient and family.
Intensive educational training has shown to improve
compliance and adaptation to NIV.(16) Transtracheal
invasive ventilation is offered to patients who wish to
stay on long term ventilatory support, however it is
resource intensive.
Diaphragmatic pacing in ALS patients was shown to
decrease survival and is not recommended for MND
patients at this time while further studies on this are
ongoing. (17)
Along with respiratory decline, a weak cough and the
consequent difficulty in clearing respiratory secretions
is a common cause of lower respiratory tract infections.
These patients need intensive respiratory therapy with
suctioning and clearance of secretions. Mucolytic
agents such as carbocisteine may be used.

the resting metabolism.(1, 20) BMI and the nutritional
plan need to be documented and discussed on every
visit.
Initial intervention for dysphagia can include altering
consistency and texture of food and additional
supplements to improve caloric intake. Ultimately, to
maintain BMI, a gastrostomy is needed. A swallowing
assessment performed at every visit by the speech
therapist can help guide the clinician in timing
discussions with the patient and family for gastrostomy
placement. Feeding via gastrostomy aims to decrease
the risk of aspiration, reduce the need for
hospitalization and maintain body weight. (1, 22) The
ideal time for gastrostomy placement is not known,
however should be considered when there is more than
10% weight loss (23). The ProGas trial (22) was the
first multicenter cohort study to indicate the benefits of
early gastrostomy. Patients who had more than 10%
loss of weight prior to PEG placement, from the time of
diagnosis to the procedure, had shorter survival and
were less likely to regain that weight. The risk of
complications during the gastrostomy procedure is low
if the FVC is ≥ 38% of predicted and the PaCo2 is
normal.(24) Different methods of gastrostomy (
percutaneous endoscopic, radiologically inserted or
per-oral image guided) are not superior to each other
and the decision is made based on the respiratory
status of the patient, ability to lie flat and physician
preference. (22, 25)
There have been numerous studies with insufficient
evidence for the use of vitamin supplements including
Vitamins A, B-complex, D, C, L-carnitine, co-enzyme
Q10 and creatine monohydrate.(1, 18) Similarly, the
benefits of high carbohydrate, high protein or high fat
diets are controversial.(18, 20) The nutritionist should
make a diet plan based on individual needs and offer
high energy supplements early if necessary.

HYPERSIALORRHEA
Difficulty in swallowing can give rise to build-up of saliva
in the mouth, which can be socially embarrassing for
the patient and can also increase the risk of aspiration
pneumonia. Oral medications are tried as first line
therapy. Options include amitriptyline, benztropine,
trihexyphenidyl, scopolamine, atropine drops or
glycopyrolate.(7, 18) If medications are unable to
control the hypersialorrhea or side effects limit their
use, then botox injections in the parotid and/or
submandibular gland or low dose radiation to the
salivary glands can be considered.(7, 18, 19)

PSEUDOBULBAR AFFECT (EMOTIONAL LABILITY)
Pseudobulbar affect (PBA) refers to episodic,
involuntary, excessive crying, laughter, yawning that is
seen in up to 50% of MND/ALS patients.(26) This
significantly impairs quality of life and effects social
functioning. Antidepressants such as tricyclic
antidepressants (amitriptyline) and serotonin re-uptake
inhibitors (citalopram) are frequently used. (7, 20)
Pioro et al reported a combination of dextromethorphan
(DM) 30mg and quinidine (Q) 10mg reduced the
frequency and severity of laughing and crying behaviors
compared to either drug alone.(27)A fixed dose
combination of DM/Q (30mg/10mg) is recommended
for treatment of PBA. (7)

NUTRITION
Rapid decline in weight and BMI (<18.5) is associated
with progression of disease and decrease in survival.(1,
20, 21) Reasons for inadequate oral intake are
multifactorial and include dysphagia, weakness of
upper limbs making patients dependent on others for
feeding, depression or cognitive decline and increase in
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COMMUNICATION

Depression and/or anxiety may result from uncertainty
or delay in diagnosis, prognosis of the disease, as part
of the cognitive changes or due to drug side effects. All
patients are screened for mood disorders and treated
accordingly. No drugs are indicated for mood disorders
specifically in MND; however they can be prescribed
based on their side effect profile, which may even help
other symptoms e.g hypersialorrhea and PBA.

The speech and language therapist guides the patient
and family in exercises and to use tools to help with
communication. Based on availability, assistive devices
are prescribed. These include word, alphabet, sound
and visual command cards, typing devices, speaker
phones, sound synthesizers or personal digital
assistance (PDA).

INSOMNIA AND FATIGUE

ASSISTIVE DEVICES AND EQUIPMENT

Insomnia and fatigue become common complaints in
MND especially as the disease progresses. Multiple
aspects of the disease already discussed contribute to
sleep disturbances. The earliest sign of respiratory
muscle weakness may just be insomnia that is related
to nocturnal hypoventilation.(15) Other factors
affecting sleep include depression, anxiety, immobility,
muscle cramps and restless legs syndrome.(15)
Decrease in restful sleep, in turn, can aggravate other
symptoms like depression, anxiety, cramps and
cognitive decline. Clinically, insomnia is treated with
medications such as zolpidem and amitriptyline while
identifying the primary cause and its treatment.
Modafinil may be used for excessive day time
somnolence or fatigue.(20)

Regular assessment by the physiotherapists and
occupational therapists will address the need for aids
for mobility and activities of daily living (ADL). The home
environment needs to be assessed for safety and
adapted according to individual person’s needs. For
example, adjustments in bathrooms with arm rails by
the toilet, elevated toilet seat, shower seat and shower
bars. Devices most often used for mobility include a
cane, walker, wheelchair and ankle brace for
ambulation.(28) For severely weak patients a sliding
transfer board at home is recommended. ADLs can be
made easy by simple interventions such as modified
eating utensils with thick handles for better grip, wrist
braces, slip-on shoes, and electric seating controls for
a beds or wheelchairs. (28) Although the cost of some
of this equipment is high, there are no studies on cost
effectiveness as yet. In the long run, complications of
falls and immobility can be avoided, decreasing
hospitalization and improving quality of life.

DISEASE MODIFYING THERAPIES
Riluzole is the first drug shown to have some benefits in
patients with ALS and was approved by the FDA in
1995. It’s mechanism of action is not clearly known but
it has shown to modulate the effects of glutamate, both
by inhibiting its release and modulating post synaptic
glutamate receptor signaling. Riluzole is also reported
to have neuroprotective effects. (32) It slows
progression of disease and lengthens survival by at
least 3 months, initially shown in two large placebo
controlled trials.(9, 33) It is safe to use at a dose of
100mg daily, with the most common side effects of
raised liver enzymes, asthenia, dizziness and
gastrointestinal discomfort.(33) Riluzole must be
offered to all patients with a diagnosis of MND/ALS.
Hope came with the discovery of a free radical
scavenger, Edaravone, which was first approved in
Japan in 2015 for treatment of ALS, followed by FDA
approval in 2017.However, it is not yet approved in
Europe, and there are widespread conflicting opinions
amongst neuromuscular specialists about its benefits
and accelerated approval. Edaravone is delivered by
intravenous infusions in cycles consisting of daily
dosing for 2 weeks followed by a 2-week drug-free
period .The initial trial conducted in Japan had a short
6 months duration of intervention with very constrictive

CRAMPS AND SPASTICITY
There is no clear evidence of benefit of a specific drug
for cramps in MND patients, but quinine, gabapentin
and vitamin E are widely used. (7, 29) Spasticity is
treated by encouraging physical therapy and use of
drugs used for increased tone in other central nervous
disorders such as baclofen, tizanidine and
benzodiazepines.
COGNITIVE AND MOOD IMPAIRMENT
Cognitive impairment is seen in up to 30% ALS
patients, mostly behavioral variant of frontotemporal
dementia.(30) Cognitive deficits in fluency, language,
social cognition, executive functions and verbal
memory have been documented. (31) The role of the
neuropsychiatrist/psychologist in the MDC is to assess
all MND patients using neuropsychological testing.
Early intervention and counseling for cognitive and
behavioral changes will improve quality of life and
decrease care giver burden.
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